Joslyn says Oragenics is making 'great progress' enrolling patients in oral mucositis clinical trial. Oral mucositis is a painful side effect in patients who are receiving chemotherapy in head and neck cancers.
Oragenics making 'great progress' enrolling patients in oral mucositis clinical trial
Quick facts: Oragenics Inc
Price: 0.453 USD
Market Cap: $20.89 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE